Lv11
90 积分 2025-10-12 加入
JSKN003, a biparatopic anti-HER2 antibody drug conjugate (ADC), in the treatment of platinum-resistant ovarian cancer (PROC): Updated findings from two clinical trials
40分钟前
已关闭
Dual target PARP1/EZH2 inhibitors inducing excessive autophagy and producing synthetic lethality for triple-negative breast cancer therapy
4天前
已完结
NCOG-37. Outcomes from online education focused on novel targeted therapies for IDH-mutant gliomas
28天前
已完结
Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study
1个月前
已完结
Oral Etoposide (VP16) in Platinum-Resistant Epithelial Ovarian Cancer (EOC)
1个月前
已完结
Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer
1个月前
已完结
Harnessing synergy: Innovative combinations to overcome PARP inhibitor resistance in cancer treatment
1个月前
已关闭
Discovery of new inhibitors of nuclease MRE11
1个月前
已完结
Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality
1个月前
已完结
STAT3, a Master Regulator of Anti-Tumor Immune Response
2个月前
已完结
皖公网安备34019202002308
